Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Rosa I. Sanchez"'
Autor:
Kelly Bleasby, Robert Houle, Michael Hafey, Meihong Lin, Jingjing Guo, Bing Lu, Rosa I. Sanchez, Kerry L. Fillgrove
Publikováno v:
Viruses, Vol 13, Iss 8, p 1566 (2021)
Islatravir (MK-8591) is a nucleoside reverse transcriptase translocation inhibitor in development for the treatment and prevention of HIV-1. The potential for islatravir to interact with commonly co-prescribed medications was studied in vitro. Elimin
Externí odkaz:
https://doaj.org/article/d17ac357847f48b79084529598f00883
Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization
Autor:
Rebecca Nofsinger, Sophie-Dorothee Clas, Rosa I. Sanchez, Abbas Walji, Kimberly Manser, Becky Nissley, Jaume Balsells, Amrithraj Nair, Qun Dang, David Jonathan Bennett, Michael Hafey, Junying Wang, John Higgins, Allen Templeton, Paul Coleman, Jay Grobler, Ronald Smith, Yunhui Wu
Publikováno v:
Pharmaceuticals, Vol 7, Iss 2, Pp 207-219 (2014)
Prodrugs are chemistry-enabled drug delivery modifications of active molecules designed to enhance their pharmacokinetic, pharmacodynamic and/or biopharmaceutical properties. Ideally, prodrugs are efficiently converted in vivo, through chemical or en
Externí odkaz:
https://doaj.org/article/f16659dde48e4fc4a5f8d5c963902bbd
Autor:
Sauzanne Khalilieh, Tamara D. Cabalu, Yuhsin Kuo, Sasha McClain, Larissa Wenning, Ilias Triantafyllou, Yang Liu, Daniel P. Dreyer, Rosa I. Sanchez, S. Aubrey Stoch, Marian Iwamoto, Ka Lai Yee, Kerry L. Fillgrove
Publikováno v:
The Journal of Clinical Pharmacology. 61:394-405
Doravirine, a novel nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus 1 (HIV-1), is predominantly cleared by cytochrome P450 (CYP) 3A4 and metabolized to an oxidative metabolite (M9). Coadministration wit
Autor:
Li Fan, Sauzanne Khalilieh, Mohammed Bouhajib, Marian Iwamoto, Shawn Searle, Ka L. Yee, Rosa I. Sanchez, Kate Vaynshteyn
Publikováno v:
Clinical Pharmacology in Drug Development. 9:151-161
Doravirine is a novel nonnucleoside reverse transcriptase inhibitor indicated for the treatment of HIV type 1 infection. A subset of people living with HIV receives methadone for the treatment of opioid addiction. The current study (NCT02715700) was
Autor:
Rosa I. Sanchez, S. Aubrey Stoch, Larissa Wenning, Ka Lai Yee, Sauzanne Khalilieh, Marian Iwamoto
Publikováno v:
Clinical Drug Investigation
Doravirine (MK-1439) is a novel non-nucleoside reverse transcriptase inhibitor indicated for the combination treatment of human immunodeficiency virus type-1 (HIV-1) infection. The recommended dose is 100 mg once daily. This review summarizes the pha
Autor:
Kenneth C. Lasseter, Thomas Marbury, Sauzanne Khalilieh, Patrice Auger, Ka Lai Yee, Rachael Liu, Marian Iwamoto, Rosa I. Sanchez, Daria Stypinski, Li Fan, Ilias Triantafyllou
Publikováno v:
The Journal of Clinical Pharmacology. 57:777-783
Doravirine is a novel, potent, nonnucleoside reverse-transcriptase inhibitor currently in development for HIV-1 infection treatment. As a substrate for CYP3A-mediated metabolism, doravirine could potentially be affected by liver-function changes. As
Autor:
T Laethem, Luc M. Van Bortel, Ka Lai Yee, Marian Iwamoto, Monali Sura, Griet van Lancker, Matt S. Anderson, Scott Rasmussen, Sauzanne Khalilieh, Li Fan, Rosa I. Sanchez
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
Identifying and understanding potential drug-drug interactions (DDIs) are vital for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This article discusses DDIs between doravirine, a nonnucleoside reverse transcriptase inhibito
Autor:
Kerry L. Fillgrove, Grace Chan, Rosa I. Sanchez, Meihong Lin, Bing Lu, Deborah J. Newton, Robert Houle, Jairam Palamanda, Kelly Bleasby
Doravirine is a novel nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus type 1 infection. In vitro studies were conducted to assess the potential for drug interactions with doravirine via major drug-metab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f76b0224ecf19334aa1e470533a76d3
https://europepmc.org/articles/PMC6437506/
https://europepmc.org/articles/PMC6437506/
Autor:
Ka Lai Yee, Sauzanne Khalilieh, Li Fan, Rosa I. Sanchez, Heather R. Jordan, Dawn Cislak, Marian Iwamoto, Maureen Martell
Publikováno v:
Clinical pharmacology in drug developmentReferences. 9(1)
Doravirine is a novel nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus type-1 (HIV-1) infection. In vitro and clinical data suggest that doravirine is unlikely to cause significant drug-drug interactions
Autor:
Heather R. Jordan, Li Fan, Rosa I. Sanchez, Maureen Martell, Sauzanne Khalilieh, Kate Vaynshteyn, Kathleen Deschamps, Ka Lai Yee, Marian Iwamoto
Publikováno v:
Journal of clinical pharmacology. 59(8)
Doravirine is a novel non-nucleoside reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus type 1 infection. Because of potential concomitant administration with acid-reducing agents, a drug-interaction trial was